GHRP-6

What GHRP-6 does

GHRP-6 raises growth hormone and can also raise cortisol and prolactin. Most human studies were brief hormone tests. A 2026 phase 3 stroke trial of EGF plus GHRP-6 missed its main endpoint. Community users report strong hunger and water retention. Lasting muscle or recovery benefits of home injections remain unproven.

• In small studies, an IV dose raised growth hormone in step with the dose; lasting benefits were not tested. (Studied in a trial)
• Studied in people as a supervised test for growth hormone deficiency, alone or with a related hormone. (Studied in a trial)
• People report much stronger hunger than with ipamorelin, and some use it on purpose to eat more. (Reported by users)

Uses in the sources

• Studied for GH stimulation testing, alone and with GHRH. This does not establish a treatment dose. (Studied in a trial) (source)
• Studied with EGF for acute ischemic stroke. The phase 3 trial missed its primary endpoint. (Studied in a trial) (source)
• Published clinician use combined it with GHRP-2 and sermorelin; IGF-1 rose, but body-composition benefits were not measured. (Clinician-published) (source)
• People use it to increase hunger. Controlled appetite outcomes specific to GHRP-6 were not found. (Reported by users) (source)

GHRP-6 dosage

Typical reported dose: 100 mcg three times a day, often with CJC

• Early IV dose range: 0.05-2.5 mcg/kg IV over 30 minutes; no chronic titration. once per test dose, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV bolus: 0.1 mcg/kg: 0.1 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV bolus: 0.3 mcg/kg: 0.3 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV bolus: 1 mcg/kg: 1 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• With GHRH: 0.1 mcg/kg: GHRP-6 0.1 mcg/kg plus GHRH 1 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• With GHRH: 0.3 mcg/kg: GHRP-6 0.3 mcg/kg plus GHRH 1 mcg/kg IV once. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)

Highest studied: Highest retrieved fixed-dose SC three-times-daily human regimen: 100 mcg with GHRP-2 and sermorelin..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix GHRP-6

Comes as: Lyophilized powder vial reported online, Controlled IV preparations in trials, Oral capsules, nasal and sublingual preparations in research.

Mixed with: Bacteriostatic water appears in community mixing reports; it is not an approved GHRP-6 instruction..

Common vial sizes: 5 mg. Common water amounts: 1, 2 mL.

• The 5 mg vial and 1-2 mL water volumes are forum examples, not validated preparation instructions.
• Trial formulations and their storage limits cannot be transferred to unknown online powders.
• Sterility, endotoxin and measured peptide content require separate testing.

Before mixing: Community users refrigerate powders; stroke-study lyophilized products were stored at 2-8°C under trial controls.

After mixing: Users refrigerate mixed vials; no validated home-vial storage duration was found.

GHRP-6 side effects and risks

Reported side effects

• Flushing: Reported in GH testing; denominator not stated., mild (source)
• Cortisol or prolactin increase: Both roughly doubled at 1 mcg/kg IV in one acute study., moderate (source)
• Blood sugar disturbance: unknown, moderate (source)
• Strong hunger and water retention: unknown, moderate (source)
• Serious events in stroke combination trials: 30/95 treated patients had severe events in COURAGE 2; authors attributed none to therapy., serious (source)
• Immune reaction or injection infection: unknown, serious (source)

Stop and get help if

• Trouble breathing, tongue swelling, fainting or widespread hives: Stop and get emergency care now.
• Sudden severe headache, new vision loss or repeated vomiting: Get emergency assessment now; a pituitary or pressure problem must be excluded.
• Chest pain, severe breathlessness or collapse: Call emergency services now.
• Persistent severe abdominal pain or repeated vomiting: Stop and get urgent medical assessment.
• Confusion, seizure, or low blood sugar that does not resolve: Get emergency help now; do not drive.
• Fever with a hot, spreading, painful injection site: Get urgent care for a possible injection infection.

Who should avoid it

• pregnant: Avoid during pregnancy. Reproductive safety is unstudied; this screen is precautionary.
• breastfeeding: Avoid while breastfeeding. Human infant exposure and safety are unknown.
• tryingToConceive: Avoid while trying to conceive. Human fertility and early-pregnancy safety are unknown.
• under18: Historical child studies do not support unsupervised use in minors.
• activeCancer: GH and IGF-1 are growth signals. Avoid with active cancer; this applies GH-treatment precautions to secretagogues.
• cancerHistory: Prior cancer needs a clinician review before raising GH or IGF-1. Recurrence risk with this compound is unknown.
• diabetes: GH-related changes can worsen insulin sensitivity. Review blood sugar control and medicines.
• heartCondition: Fluid retention may strain the heart. Heart-disease safety is not established for home-use schedules.
• uncontrolledBloodPressure: Review uncontrolled blood pressure before use. Fluid retention and pressure changes need assessment.
• kidneyDisease: Kidney-disease dose adjustments and repeated-dose safety are not established.
• liverDisease: Liver-disease dose adjustments and repeated-dose safety are not established.
• diabeticRetinopathy: Review proliferative eye disease before raising GH or IGF-1. This is a GH-class precaution.
• pancreatitisHistory: Review prior pancreatitis. GH-class safety concerns do not establish a risk rate for this compound.
• sleepApnea: Review sleep apnea and new swelling. GH-related tissue or fluid changes are a class concern.
• surgeryPlanned: Tell the surgical team about use and all stacks. Perioperative safety depends on the specific study setting.
• testedAthlete: WADA bans this compound at all times, including out of competition.
• other: Do not add a GH secretagogue when GH or IGF-1 is already excessive. Investigate the cause.
• other: A pituitary mass needs specialist review. GH testing and GH-raising drugs are not interchangeable.

Interactions

• Insulin and sulfonylureas: GH-class precaution: insulin sensitivity and medicine needs can change. Exact interaction trials for this peptide are lacking.
• Other GH secretagogues, GH, and IGF-1: Overlapping GH/IGF-1 effects can add hormone, swelling and blood sugar risks. Combination benefit is not established.
• Glucocorticoids and oral estrogen: These can change GH responses or IGF-1 interpretation. Do not change prescribed hormone replacement to alter a peptide response.
• Anticoagulants and antiplatelets: General injection precaution: blood thinners increase bleeding/bruising risk. A direct interaction with this peptide has not been established.
• Pegvisomant: In a small experiment, GH-receptor blockade changed GHRP-6 glucose and insulin effects. Review this combination with a specialist.

Product quality risks

• Unregulated products may have the wrong identity, dose or sterility. A purity percentage alone cannot establish injection safety.
• Studies identified glycine-modified GHRP-2, GHRP-6 and ipamorelin in black-market or seized preparations.
• No representative market-wide contamination or underdosing rate was found for this compound.

What to expect

The phase 3 stroke study tested GHRP-6 with EGF. Its phase cannot be assigned to GHRP-6 alone. A direct-administration study count is not established here.

Key studies

• Early human dose finding: A brief IV infusion produced a dose-related GH rise. (source)
• Placebo-controlled GH dose response: The dose-response and acute GHRH interaction do not prove long-term muscle benefits. (source)
• Nasal dose and repeated-dose study: Nasal administration produced a hormone response in a very small study. (source)
• Early oral dose comparison: Oral GHRP-6 was active at much larger doses than IV exposure. (source)
• 34-hour IV infusion: A prolonged infusion maintained GH activity, but clinical benefit was not studied. (source)
• GH responses in obesity: A larger GH response in obesity does not establish fat-loss efficacy. (source)

GHRP-6 FAQ

• Is GHRP-6 FDA-approved? No FDA-approved product or dose label found; no approval for physique or performance use.
• How do people take it? Under the skin, three times daily. Source: reported by users, not an established dose.
• What's the difference between GHRP-6 and Sermorelin? GHRP-6: a peptide studied in growth hormone tests and an experimental stroke combination. Sermorelin: an experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits. Why people pair them: a clinician-published triple combination raised IGF-1.
• Can I take it with Sermorelin with GHRP-2? A clinician-published triple combination raised IGF-1. Selected retrospective cohort; no isolated GHRP-6 effect or adequate safety comparison. Source: clinician-published. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named on the 2026 list; prohibited in and out of competition.
• How long does a mixed vial last? Users refrigerate mixed vials; no validated home-vial storage duration was found.